Prot# CSTI571H2201: A Phase II, Open-Label, Multi-Centre, Single-Arm Study, Evaluating the Efficacy of Glivec® plus Hydroxyurea (HU) in Patients with Progressive Giloblastoma Multiforme (GBM), Not Receiving Enzyme Inducing Anticonvulsant Drugs (

Project: Research project

Project Details

StatusFinished
Effective start/end date10/20/057/31/09

Funding

  • Novartis Pharmaceuticals Corporation (CSTI571H2201)